Tiziana Life Sciences (TLSA) AI Stock Analysis
Tiziana Life Sciences
(NASDAQ:TLSA)
No summary available
Tiziana Life Sciences (TLSA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $85.26M
- Dividend Yield
- ―
- Average Volume (3M)
- 785.53K
- Price to Earnings (P/E)
- -3.3
- Beta (1Y)
- -0.16
- Revenue Growth
- ―
- EPS Growth
- -78.92%
- Country
- US
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Tiziana Life Sciences Business Overview & Revenue Model
Company Description
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a...
Tiziana Life Sciences Risk Analysis
Tiziana Life Sciences disclosed 65 risk factors in its most recent earnings report. Tiziana Life Sciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksTiziana Life Sciences Peers Comparison
Overall Rating
OABI69Neutral
AVIR60Neutral
SLN55Neutral
HRTX43Neutral
PRQR42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| OABI | 69Neutral | $742.94M | -14.97 | -16.73% | ― | 90.63% | 42.74% |
| AVIR | 60Neutral | $329.64M | -1.97 | -64.25% | ― | ― | -29.71% |
| SLN | 55Neutral | $1.23B | -5.19 | -106.94% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HRTX | 43Neutral | $52.72M | -1.58 | -300.90% | ― | 0.99% | -3014.75% |
| PRQR | 42Neutral | $196.16M | -2.98 | -68.44% | ― | 19.49% | -4.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TLSA | Tiziana Life Sciences (US) | 0.67 | -1.13 | -62.78% | |
| HRTX | Heron Therapeutics Inc | 0.29 | -0.84 | -74.12% | |
| PRQR | ProQR Therapeutics BV | 1.32 | -1.06 | -44.54% | |
| SLN | Silence Therapeutics Plc | 19.76 | 13.25 | 203.53% | |
| AVIR | Atea Pharmaceuticals, Inc. | 4.10 | 0.89 | 27.73% | |
| OABI | Omniab, Inc. | 5.09 | 3.61 | 243.92% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.